Visuo-perceptual processing in patients with schizophrenia treated with typical or atypical antipsychotics;Procesamiento visuo-perceptivo en los pacientes con esquizofrenia tratados con antipsicóticos típicos y los tratados con atípicos

Actas Espanolas de Psiquiatria

Volumn 29, Issue 1, 2001, Pages 19-24

  Romera, M I ^a   Gurpegui, M ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Antipsychotic medication; Schizophrenia; Visuo spatial tasks

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; DAILY LIFE ACTIVITY; DRUG EFFECT; FEMALE; HUMAN; MALE; MEMORY; PATHOPHYSIOLOGY; PHYSIOLOGY; PILOT STUDY; PSYCHOLOGY; REGRESSION ANALYSIS; SCHIZOPHRENIA; VISION;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MEMORY; PILOT PROJECTS; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VISUAL PERCEPTION;

EID: 0035234973     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. a ed. Washington DC: American Psychiatric Press; 1997. p. 128-30.
2. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Supl 4):1-63.
3. Bustillo JR, Thaker G, Buchanan RW, Moran M, Kirkpatrick B, Carpenter WT. Visual information processing impairments in deficit and nondeficit schizophrenia. Am J Psychiatry 1997;154:647-54.
4. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
5. O'Donnell BF, Swearer JM, Smith LT, Nestor PG, Shenton ME, McCarley RW. Selective deficits in visual perception and recognition in schizophrenia. Am J Psychiatry 1996;153:687-92.
6. Keefe RSE, Leesroitman SE, Dupre RL. Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay. Schizophr Res 1997;26;9-14.
7. Hollister LE. Farmacología clínica de drogas psicoterapéuticas. Madrid: Editorial Médica Panamericana; 1986.
8. Rey A. Rey - Test de copia y reproducción de memoria de figuras geométricas complejas, ed 6 (versión española de De la Cruz MV, Seisdedos M, Cordero A). Madrid: TEA Ediciones; 1997.
9. Peralta V, Cuesta MJ. Validación de la escala de los síndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso-Esp Neurol Psiquiatr 1994;21:44-50.
10. Peralta V, Cuesta MJ. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res 1994;53:31-40.
11. Leff J. Habilidades específicas básicas de la vida diaria. Sevilla: Servicio Andaluz de Salud, Dirección General de Asistencia Sanitaria, Programa de Salud Mental; 1985-1993.
12. Green MF, Marshall BD, Whirsing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
13. Breier A. Cognitive deficit in schizophrenia and its neurochemical basis. Br J Psychiatry 1999;178(Supl 37):16-8.
14. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999;45:1-16.
15. Rosenheck R, Cramer JX, Thomas J, Henderson W, Frisman L, Fye C, Charney D. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337: 809-15.
16. Moore NA. Behavioral pharmacology of the new generation of antipsychotics agents. Br J Psychiatry 1999;174(Supl 38):5-11.
17. Harrison PJ. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Br J Psychiatry 1999;174(Supl 38):12-22.
18. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-12.
19. Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry 1999;174(Supl 38):44-51.
20. Citrome L. New antipsychotic medications: What advantages do they offer? Postgrad Med 1997;101:207-10, 213-4.
21. Fernández A, González J. Rehabilitación psicosocial en los trastornos esquizofrénicos. En: Sáiz Ruiz J, ed. Esquizofrenia: enfermedad del cerebro y reto social. Barcelona: Masson; 1999.
22. MacDonald EM, Jackson HJ, Hayes RL, Baglioline AJ, Madden C. Social skill as a determinant of social networks and perceived social support in schizophrenia. Schizophr Bull 1998;29:275-86.
23. Penn DL, Mueser KT. Research update on the psychosocial treatment of schizophrenia. Am J Psychiatry 1996;153:607-17.
24. Norman RMG, Malla AK, Cortese L, Cheng S, Díaz K, McIntosh E, et al. Symptoms and cognition as predictors of community functioning: A prospective analysis. Am J Psychiatry 1999;156:400-5.
25. Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res 1997;25:21-31.